VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Overview
Europe - FRA:VX1 - US92532F1003 - Common Stock
VX1.DE Key Statistics, Chart & Performance
The current stock price of VX1.DE is 349.225 EUR. In the past month the price increased by 1.98%. In the past year, price decreased by -16.54%.
VX1.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 22.26 | 355.08B | ||
| 1AMGN.MI | AMGEN INC | 13.65 | 136.64B | ||
| AMG.DE | AMGEN INC | 13.64 | 136.47B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.61 | 119.63B | ||
| ARGX.BR | ARGENX SE | 92.61 | 41.71B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.65B | ||
| IDP.DE | BIOGEN INC | 9.92 | 19.84B | ||
| 0QF.DE | MODERNA INC | N/A | 9.51B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.19B | ||
| 2X1.DE | ABIVAX SA | N/A | 5.57B | ||
| 22Z.DE | ZEALAND PHARMA A/S | 5.36 | 3.15B |
Related stock screener links
About VX1.DE
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VX1.DE FAQ
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of VX1.DE is 349.225 EUR. The price increased by 1.03% in the last trading session.
What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VX1 and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is VX1.DE stock listed?
VX1.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?
39 analysts have analysed VX1.DE and the average price target is 418.38 EUR. This implies a price increase of 19.8% is expected in the next year compared to the current price of 349.225. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a market capitalization of 89.54B EUR. This makes VX1.DE a Large Cap stock.
How many employees does VERTEX PHARMACEUTICALS INC have?
VERTEX PHARMACEUTICALS INC (VX1.DE) currently has 6100 employees.
What are the support and resistance levels for VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
VERTEX PHARMACEUTICALS INC (VX1.DE) has a support level at 317 and a resistance level at 345.66. Check the full technical report for a detailed analysis of VX1.DE support and resistance levels.
Is VERTEX PHARMACEUTICALS INC (VX1.DE) expected to grow?
The Revenue of VERTEX PHARMACEUTICALS INC (VX1.DE) is expected to grow by 10.06% in the next year. Check the estimates tab for more information on the VX1.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERTEX PHARMACEUTICALS INC (VX1.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VX1.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VX1.DE, evaluating the profitability, health, valuation and growth aspects
- VERTEX PHARMACEUTICALS INC (VX1.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Sales and EPS estimates to see what analysts future expectations are.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERTEX PHARMACEUTICALS INC (VX1.DE) Stock Chart to make your own analysis
- VERTEX PHARMACEUTICALS INC (VX1.DE) Latest news and press-releases to stay up to date.
Does VERTEX PHARMACEUTICALS INC (VX1.DE) stock pay dividends?
VX1.DE does not pay a dividend.
When does VERTEX PHARMACEUTICALS INC (VX1.DE) report earnings?
VERTEX PHARMACEUTICALS INC (VX1.DE) will report earnings on 2025-10-29, after the market close.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (VX1.DE)?
The PE ratio for VERTEX PHARMACEUTICALS INC (VX1.DE) is 24.18. This is based on the reported non-GAAP earnings per share of 14.44 and the current share price of 349.225 EUR. Check the full fundamental report for a full analysis of the valuation metrics for VX1.DE.
VX1.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to VX1.DE. When comparing the yearly performance of all stocks, VX1.DE is a bad performer in the overall market: 91.53% of all stocks are doing better.
VX1.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to VX1.DE. VX1.DE gets an excellent profitability rating and is at the same time showing great financial health properties.
VX1.DE Financial Highlights
Over the last trailing twelve months VX1.DE reported a non-GAAP Earnings per Share(EPS) of 14.44. The EPS increased by 7966.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.86% | ||
| ROA | 15.13% | ||
| ROE | 21.18% | ||
| Debt/Equity | 0 |
VX1.DE Forecast & Estimates
39 analysts have analysed VX1.DE and the average price target is 418.38 EUR. This implies a price increase of 19.8% is expected in the next year compared to the current price of 349.225.
For the next year, analysts expect an EPS growth of 6246.89% and a revenue growth 10.06% for VX1.DE